Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVR Anteris Technologies Global	$4.51 -4.9%	$3.87	$2.34 ▼ $8.79	$162.64M	N/A	206,550 shs	105,572 shs
LUCD Lucid Diagnostics	$1.52	$1.35	$0.68 ▼ $1.80	$164.45M	1.28	538,012 shs	881,456 shs
MDAI Spectral AI	$1.66 -2.4%	$1.29	$0.82 ▼ $3.25	$42.03M	0.59	839,837 shs	249,452 shs
OBIO Orchestra BioMed	$2.83 -4.1%	$2.98	$2.37 ▼ $8.87	$108.43M	0.67	165,357 shs	212,630 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVR Anteris Technologies Global	-4.85%	+39.63%	-18.15%	-35.57%	+450,999,900.00%
LUCD Lucid Diagnostics	0.00%	+14.29%	+20.63%	+2.70%	+69.28%
MDAI Spectral AI	-2.35%	+21.17%	+27.69%	-4.60%	-1.78%
OBIO Orchestra BioMed	-4.07%	+3.66%	+11.86%	-39.66%	-59.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVR Anteris Technologies Global	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	2.7923 of 5 stars	3.6	3.0	0.0	0.0	3.1	1.7	0.6
MDAI Spectral AI	2.58 of 5 stars	3.7	2.0	0.0	0.0	2.6	3.3	0.0
OBIO Orchestra BioMed	3.0835 of 5 stars	4.6	4.0	0.0	0.0	2.2	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVR Anteris Technologies Global	3.00	Buy	$16.50	265.85% Upside
LUCD Lucid Diagnostics	3.20	Buy	$3.50	130.26% Upside
MDAI Spectral AI	3.33	Buy	$4.75	186.14% Upside
OBIO Orchestra BioMed	3.20	Buy	$14.20	401.77% Upside

Current Analyst Ratings Breakdown

Latest MDAI, LUCD, OBIO, and AVR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.00 ➝ $2.00
5/14/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
5/13/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/5/2025	OBIO Orchestra BioMed	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $12.00
4/23/2025	OBIO Orchestra BioMed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/22/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/21/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.50
4/11/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
4/4/2025	OBIO Orchestra BioMed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
4/3/2025	OBIO Orchestra BioMed	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/2/2025	MDAI Spectral AI	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.50 ➝ $3.50

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVR Anteris Technologies Global	$2.71M	59.99	N/A	N/A	N/A	∞
LUCD Lucid Diagnostics	$4.17M	39.41	N/A	N/A	($0.47) per share	-3.23
MDAI Spectral AI	$29.96M	1.40	N/A	N/A	($0.10) per share	-16.60
OBIO Orchestra BioMed	$2.89M	37.57	N/A	N/A	$1.90 per share	1.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVR Anteris Technologies Global	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	-$52.67M	-$1.34	N/A	N/A	N/A	-1,069.87%	N/A	-123.54%	8/11/2025 (Estimated)
MDAI Spectral AI	-$20.85M	-$0.54	N/A	N/A	N/A	-40.78%	N/A	-77.87%	N/A
OBIO Orchestra BioMed	-$49.12M	-$1.78	N/A	N/A	N/A	-2,179.33%	-107.04%	-70.88%	N/A

Latest MDAI, LUCD, OBIO, and AVR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	AVR Anteris Technologies Global	N/A	-$0.61	N/A	-$0.61	N/A	N/A
5/12/2025	Q1 2025	OBIO Orchestra BioMed	-$0.46	-$0.49	-$0.03	-$0.49	$0.39 million	$0.87 million
3/31/2025	Q4 2024	OBIO Orchestra BioMed	-$0.43	-$0.43	N/A	-$0.43	$0.79 million	$0.25 million
3/27/2025	Q4 2024	MDAI Spectral AI	-$0.13	-$0.06	+$0.07	-$0.41	$6.83 million	$7.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVR Anteris Technologies Global	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
MDAI Spectral AI	N/A	N/A	N/A	N/A	N/A
OBIO Orchestra BioMed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVR Anteris Technologies Global	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	1.18	1.14
MDAI Spectral AI	N/A	0.73	0.69
OBIO Orchestra BioMed	N/A	4.23	4.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVR Anteris Technologies Global	N/A
LUCD Lucid Diagnostics	74.01%
MDAI Spectral AI	67.08%
OBIO Orchestra BioMed	53.55%

Insider Ownership

Company	Insider Ownership
AVR Anteris Technologies Global	N/A
LUCD Lucid Diagnostics	6.80%
MDAI Spectral AI	30.70%
OBIO Orchestra BioMed	8.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVR Anteris Technologies Global	138	36.06 million	N/A	N/A
LUCD Lucid Diagnostics	70	108.19 million	54.12 million	No Data
MDAI Spectral AI	83	25.32 million	8.04 million	Not Optionable
OBIO Orchestra BioMed	4	38.31 million	35.47 million	Not Optionable

MDAI, LUCD, OBIO, and AVR Headlines

Recent News About These Companies

Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships

May 28 at 7:44 AM | seekingalpha.com

Head to Head Contrast: SeaStar Medical (NASDAQ:ICU) vs. Orchestra BioMed (NASDAQ:OBIO)

May 24, 2025 | americanbankingnews.com

Orchestra BioMed (NASDAQ:OBIO) Announces Quarterly Earnings Results

May 14, 2025 | marketbeat.com

Orchestra BioMed Holdings - Breakthrough Device Designation Gives Speculative Optimism

May 14, 2025 | seekingalpha.com

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates

May 12, 2025 | zacks.com

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

May 12, 2025 | globenewswire.com

Orchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough Designation

May 11, 2025 | msn.com

Orchestra BioMed Expands Patent Portfolio with 10 New Patents for Hypertension Treatment, Totaling 120 Global Patents

May 9, 2025 | nasdaq.com

Why Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 19.92%

May 9, 2025 | aaii.com

Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

May 8, 2025 | finance.yahoo.com

Barclays Has Lowered Expectations for Orchestra BioMed (NASDAQ:OBIO) Stock Price

May 7, 2025 | marketbeat.com

Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

May 7, 2025 | globenewswire.com

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

May 5, 2025 | zacks.com

Boxer Capital Management LLC Makes New $953,000 Investment in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO)

May 4, 2025 | marketbeat.com

Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment

May 1, 2025 | msn.com

Orchestra BioMed to Present at Jefferies Global Healthcare Conference

May 1, 2025 | msn.com

Why Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 7.51%

May 1, 2025 | aaii.com

FDA approves head-to-head trial of Orchestra BioMed’s balloon

April 30, 2025 | investing.com

Orchestra BioMed (NASDAQ:OBIO) Shares Down 6.1% - Time to Sell?

April 30, 2025 | marketbeat.com

Orchestra BioMed wins FDA IDE for sirolimus-angioballoon

April 29, 2025 | massdevice.com

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

April 29, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDAI, LUCD, OBIO, and AVR Company Descriptions

Anteris Technologies Global NASDAQ:AVR

$4.51 -0.23 (-4.85%)

As of 05/29/2025 04:00 PM Eastern

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.

Lucid Diagnostics NASDAQ:LUCD

$1.52 0.00 (0.00%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$1.53 +0.01 (+0.92%)

As of 04:05 AM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Spectral AI NASDAQ:MDAI

$1.66 -0.04 (-2.35%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$1.61 -0.05 (-3.01%)

As of 05:13 AM Eastern

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.

Orchestra BioMed NASDAQ:OBIO

$2.83 -0.12 (-4.07%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$2.89 +0.06 (+1.98%)

As of 05/29/2025 05:41 PM Eastern

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time